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is a relative dearth of data in the literature with which to guide
therapy. A multicenter review of this uncommon problem is
needed to better clarify the potential risks and benefits of various
treatment options.
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We appreciate Dr Sternbergh’s response to our article and
the interesting perspective provided by his experience with two
additional patients, both of whom developed deep cervical infec-
tions caused by alpha-hemolytic streptococcus within 3 weeks
after carotid endarterectomy but were successfully treated by
antibiotics and local wound measures without excision of their
Dacron patches. Provided a satisfactory greater saphenous vein
had been present in either groin, we probably would have
replaced each of these patches with a vein patch simply because of
the traditional concern that antibiotics, debridement, and even
muscular coverage may not be sufficient to overcome bacterial
contamination in a fabric arterial prosthesis. While we agree that
early reoperations can be difficult, most of the morbidity in our
series that was mentioned by Dr Sternbergh—the two cranial
nerve injuries and a stroke related to preoperative angiography—
actually occurred in patients who presented with late patch infec-
tions and required reconstruction with vein grafts.
The surgical approach that was taken for the two early postop-
erative infections described by Dr Sternbergh brings to mind the
strategy that was introduced several years ago by Bandyk et al1 for
the management of late femoral graft biofilm infections caused by
Staphylococcus epidermidis, another organism that generally has low
clinical virulence. This strategy also emphasizes adequate debride-
ment and coverage with viable muscle—in this case, the sartorius—
but one of its important principles is replacement of all infected
Dacron with nonporous polytetrafluorethylene (PTFE) in order to
avoid persistent bacterial colonization in the interstices of a fabric
graft. (It seems safe to say that an autogenous replacement graft
would be just as appropriate as PTFE, or even more so, if one hav-
ing an adequate diameter were available.) As Dr Sternbergh is the
first to point out, the fact that this principle was not followed in
either of his patients does not invalidate it. He made a value judg-
ment based on the conditions as he found them, and it appears to
have been correct. However, he undoubtedly followed both of
these patients very closely and was prepared to excise their Dacron
patches if there had been any evidence of lingering infection.
Norman R. Hertzer, MD
Department of Vascular Surgery
The Cleveland Clinic Foundation
Cleveland, Ohio
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Regarding “Management of leg ulcers in patients
with rheumatoid arthritis or systemic sclerosis: the
importance of concomitant arterial and venous
disease”
To the Editors:
In their recent paper, Hafner et al1 are to be commended for
their thorough vascular assessment of patients with rheumatolog-
ical disease who have a leg ulcer. Like ourselves,2 they found that
leg ulcers in RA often have a multifactorial etiology with little
clinical evidence of vasculitis. It is important to stress, however,
that serological evidence of systemic vasculitis such as hypocom-
plementemia or positive tests for antineutrophil cytoplasmic anti-
bodies are usually lacking in systemic rheumatoid vasculitis and
cannot be used to exclude this diagnosis. Clinical clues such as
nail-fold infarcts, pericarditis, mononeuritis multiplex, or marked
constitutional symptoms should be looked for. If found, patients
should be referred to a rheumatologist for consideration of
immunosuppressive therapy. The absence of these features, how-
ever, should prompt an assessment of large vessel function such as
the authors describe. We also have anecdotal evidence of appro-
priate vascular intervention leading to ulcer healing in RA and
support their call for a formal study of the effectiveness of surgi-
cal intervention in these patients when evidence of systemic vas-
culitis is absent.
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We acknowledge Dr McRorie’s valuable comments in
response to our publication on leg ulcers in patients with rheuma-
toid arthritis or systemic sclerosis. Obviously, we agree that
patients with clinical signs of systemic vasculitis should be referred
to a rheumatologist for further assessment and, where appropri-
ate, for immunosuppressive therapy. Among the nine patients
with rheumatoid arthritis and leg ulcers presented in our paper,
none had signs of nail-fold infarcts, pericarditis, mononeuritis
multiplex, renal involvement, or other symptoms of systemic vas-
culitis. Several among them (4/9) received additional immuno-
suppressive therapy for their ulcers, without improvement. It was
remarkable that some of the patients (5/9) had never been sub-
jected to vascular assessment. Often the initial cause for leg ulcer-
ation in rheumatoid arthritis remains unclear and must be left to
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speculation (ie, as to whether it is due to minor trauma in
atrophic skin, cutaneous small-vessel vasculitis, systemic vasculitis,
or pyoderma gangrenosum).
At any rate, once the ulcer is established, impaired macrocir-
culation—arterial and/or venous—may greatly influence the lack
of healing. In accordance with Dr McRorie we believe that a mul-
tidisciplinary approach should be encouraged for patients with
rheumatological disease who have leg ulcers. A prospective study
should be undertaken to investigate the role of concomitant arte-
rial and venous disease and the effectiveness of vascular surgery in
the treatment of these patients.
Jürg Hafner, MD
Department of Dermatology




Regarding “Comparing patency rates between
external iliac and common iliac stents”
To the Editors:
In the article by Lee and colleagues (J Vasc Surg
2000;31:889-94), the authors have tried to test the hypothesis
that external iliac and common iliac artery stents may have differ-
ent long-term patency based on their anatomic differences. This
is an important question that remains unresolved, and the authors
are to be commended for their effort.
However in our view, the article lacks vital information to
draw any valid conclusions, basically because essential data to
ascertain that both groups are comparable are not provided.
It is stated in the article that “patients who had a failed
attempt at stent placement were not captured in the radiologic
database and could not be included in the analysis.” This omis-
sion is hardly acceptable when comparing patency rates. We
believe that operative failures are an integral part of patency and
their exclusion is misleading.
The reporting standards for lower extremity arterial endovas-
cular procedures1 point out that “to allow comparison of groups
of patients (. . .) objective hemodynamic test results must be pro-
vided. Doppler pressure measurements in the form of resting
ankle brachial indexes are a minimum requirement.” In this
regard, the authors do not provide any preprocedural or postpro-
cedural hemodynamic information from patients’ limbs or from
stenoses treated in spite of defining what a hemodynamic steno-
sis is. It is crucial to know the functional significance of these
stenoses in order to make a fair comparison. Unfortunately, this
information is not available in the article.
The same problem is evident when the issue of indications for
reintervention is addressed. A hemodynamically significant steno-
sis is defined by the authors, but no data are given about what
number of patients or segments needed a reintervention and what
the hemodynamic status of those reintervened limbs was. So it
appears that anatomic rather than hemodynamic and clinical cri-
teria were mainly considered when patients were reintervened.
Furthermore, we are puzzled by the inclusion of eight patients
with 0 clinical category, without giving any justification in six of
them, apparently “after consultation with the attending vascular
surgeon.”
Anatomic patency is just a part of the assessment of lower
extremity revascularization, and obviously it is important to make
sure how long any arterial intervention remains patent. The main
objective, however, of any arterial intervention is to improve the
hemodynamic and functional status of the limb, and this has to be
evaluated by limb pressure changes or other objective criteria.
We are concerned with the publication of these data quoting
extraordinarily high patency rates with major flaws in methodol-
ogy. We believe that it is important to dismiss articles without
appropriate methodology because they mislead rather than
enlighten our understanding of clinical problems.
Salvador Luján, MD
Enrique Criado, MD, FACS
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The comments made by Drs Luján, Criado, Izquierdo, and
Puras are much appreciated and only point to the complex nature
determining iliac artery stent patency and overall outcomes. Our
retrospective study was originally borne out of a disagreement
between the interventional radiology and vascular surgery depart-
ments regarding the long-term patency rates and overall efficacy
of external iliac artery stents. The bias in the vascular surgery
department had been that external iliac artery stents had poor
patency rates and did little to affect outcome. However, after a
search of the literature, little information could be found regard-
ing stents placed in the external iliac artery. The only information
available was author reports examining risk factors for iliac artery
stent failure. In these multivariate analyses, placement of a stent
in the external iliac did not increase the risk for early stent failure.
However, concerns of inadequate patient numbers (type II error)
were always raised as a caveat in the discussion. To our knowl-
edge, our manuscript is the first description of overall patency in
the external iliac artery with a direct comparison to the patency of
the common iliac artery.
We disagree on several points brought up by Drs Luján and
colleagues. We are unclear about what is meant by the “lack of
essential data to ascertain that both groups are comparable are
not provided. . .” We used the recommended standards for
reports dealing with lower extremity ischemia: the revised ver-
sion1 to compare levels of ischemia and to grade known risk fac-
tors within groups of patients. This information was clearly shown
in tables within our manuscript.
The omission of failed attempts at stent placement is a weak-
ness of our study, and we wish we could report those data in our
manuscript. However, several papers have shown that initial suc-
cess rates should be high at around 98% to 100%, so failing to
identify the patients that were unsuccessfully stented probably
does not affect the overall conclusions of our study.
Dr Luján and colleagues also mention our failure to include
hemodynamic criteria in our manuscript. However, by reporting
“anatomic patency,” we did meet the recommended standards1
for reporting patency rates, that is, “patency rates [should be]
based on objective findings, like arteriography, duplex ultrasound,
or magnetic resonance imaging.”
Nevertheless, the inclusion of hemodynamic information is
an interesting one but still does not completely answer the ulti-
mate question: Do external iliac artery stents improve overall
outcomes? Although hemodynamic data are other indicators of
stent patency, we feel more information regarding stent success
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